Bristol-Myers Squibb Company held its Annual Meeting on May 7, 2024, where several key decisions were made by its shareholders. The election of the company's 10 nominees to the Board of Directors was confirmed, with each director receiving a significant majority of votes for their appointment until the 2025 Annual Meeting. Additionally, the advisory vote to approve the compensation of the company's named executive officers was passed. Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2024. A management proposal to amend the company's Amended and Restated Certificate of Incorporation for limiting executive officers' monetary liability for breach of duty of care was approved. However, two shareholder proposals, one for adopting a policy that the Chairperson of the Board be an independent director, and another concerning Executive Retention of Significant Stock, were not approved. The meeting concluded with the inclusion of a Certificate of Amendment effective as of May 7, 2024, as part of the Current Report on Form 8-K.

Bristol-Myers Squibb Company held its Annual Meeting on May 7, 2024, where several key decisions were made by its shareholders. The election of the company's 10 nominees to the Board of Directors was confirmed, with each director receiving a significant majority of votes for their appointment until the 2025 Annual Meeting. Additionally, the advisory vote to approve the compensation of the company's named executive officers was passed. Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2024. A management proposal to amend the company's Amended and Restated Certificate of Incorporation for limiting executive officers' monetary liability for breach of duty of care was approved. However, two shareholder proposals, one for adopting a policy that the Chairperson of the Board be an independent director, and another concerning Executive Retention of Significant Stock, were not approved. The meeting concluded with the inclusion of a Certificate of Amendment effective as of May 7, 2024, as part of the Current Report on Form 8-K.